Retrospective evaluation of systemic corticosteroids for the management of acute exacerbations of chronic obstructive pulmonary disease

American Journal of Health-System Pharmacy

Volumn 63, Issue 7, 2006, Pages 645-652

  Vondracek, Sheryl F ^a,b   Hemstreet, Brian A ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Dosage; Dosage schedules; Drug administration routes; Hospitals; Lung diseases; Steroids, cortico

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DEXAMETHASONE; FLUTICASONE PROPIONATE; HYDROCORTISONE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; LONG ACTING DRUG; METHYLPREDNISOLONE; OXYGEN; PLACEBO; PREDNISOLONE; PREDNISONE; SALBUTAMOL SULFATE; SALMETEROL XINAFOATE; THEOPHYLLINE;

ADULT; AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG ADMINISTRATION ROUTE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; FEMALE; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 33645498597     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp050316     Document Type: Article

References (40)

1. National Heart, Lung, and Blood Institute. National Institutes of Health. Data fact sheet. Chronic obstructive pulmonary disease. www.nhlbi.nih.gov/ health/public/lung/other/copd_fact.htm (accessed 2005 May 30).
2. Seemungal TA, Donaldson GC, Paul EA et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998; 157:1418-22.
3. Seemungal TA, Donaldson GC, Bhowmik A et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000; 161:1608-13.
4. Connors AF Jr, Dawson NV, Thomas C et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996; 154:959-67.
5. Wood-Baker RR, Gibson PG, Hannay M et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochr Database Syst Rev. 2005; CD001288. DOI:10.1002/14651858.
6. Aaron SD, Vandemheen KL, Hebert P et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003; 348:2618-25.
7. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999; 354:456-60.
8. Willaert W, Daenen M, Bomans P et al. What is the optimal treatment strategy for chronic obstructive pulmonary disease exacerbations? Eur Respir J. 2002; 19:928-35.
9. Thompson WH, Nielson CP, Carvalho P et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996; 154:407-12.
10. Niewoehner DE, Erbland ML, Deupree RH et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999; 340: 1941-7.
11. Bullard MJ, Liaw SJ, Tsai YH et al. Early corticosteroid use in acute exacerbations of chronic airflow obstruction. Am J Emerg Med. 1996; 14:139-43.
12. Albert RK, Martin TR, Lewis SW. Controlled clinical trial of methylprednisolone in patients with chronic bronchitis and acute respiratory insufficiency. Ann Intern Med. 1980; 92:753-8.
13. Sayiner A, Aytemur ZA, Cirit M et al. Systemic glucocorticoids in severe exacerbations of COPD. Chest. 2001; 119:726-30.
14. Shortall SP, Blum J, Oldenburg FA et al. Treatment of patients hospitalized for exacerbations of chronic obstructive pulmonary disease: comparison of an oral/metered-dose inhaler regimen and an intravenous/nebulizer regimen. Respir Care. 2002; 47:154-8.
15. Soto FJ, Varkey B. Evidence-based approach to acute exacerbations of COPD. Curr Opin Pulm Med. 2003; 9:117-24.
16. Singh JM, Palda VA, Stanbrook MB et al. Corticosteroid therapy for patients with acute exacerbations of chronic obstructive pulmonary disease: a systematic review. Arch Intern Med. 2002; 162:2527-36.
17. Stoller JK. Clinical practice. Acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002; 346:988-94.
18. McCrory DC, Brown C, Gelfand SE et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001; 119:1190-209.
19. Snow V, Lascher S, Mottur-Pilson C. The evidence base for management of acute exacerbations of COPD: clinical practice guideline, part 1. Chest. 2001; 119:1185-9.
20. Hall CS, Kyprianou A, Fein AM. Acute exacerbations in chronic obstructive pulmonary disease: current strategies with pharmacological therapy. Drugs. 2003; 63:1481-8.
21. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004; 23:932-46.
22. Pauwels RA, Buist AS, Calverley PM et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med. 2001; 163:1256-76.
23. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004; 141:764-70.
24. McEvoy CE, Niewoehner DE. Adverse effects of corticosteroid therapy for COPD. A critical review. Chest. 1997; 111:732-43.
25. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochr Database Syst Rev. 2001; CD001740. DOI:10.1002/14651858.
26. Dubois EF, Roder E, Dekhuijzen PN et al. Dual energy x-ray absorptiometry outcomes in male COPD patients after treatment with different glucocorticoid regimens. Chest. 2002; 121:1456-63.
27. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003; 25:27-33.
28. Pittas AG, Siegel RD, Lau J. Insulin therapy for critically ill hospitalized patients: a meta-analysis of randomized controlled trials. Arch Intern Med. 2004; 164:2005-11.
29. Van Staa TP, Leufkens HG, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000; 15:993-1000.
30. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002; 13:777-87.
31. Van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000; 39:1383-9.
32. Krasner AS. Glucocorticoid-induced adrenal insufficiency. JAMA. 1999; 282:671-6.
33. Kountz DS, Clark CL. Safely withdrawing patients from chronic glucocorticoid therapy. Am Fam Physician. 1997; 55: 521-5,529-30.
34. Stanbury RM, Graham EM. Systemic corticosteroid therapy-side effects and their management. Br J Ophthalmol. 1998; 82:704-8.
35. Helfer EL, Rose LI. Corticosteroids and adrenal suppression. Characterising and avoiding the problem. Drugs. 1989; 38: 838-45.
36. Holland EG, Taylor AT. Glucocorticoids in clinical practice. J Fam Pract. 1991; 32: 512-9.
37. Karan RS, Pandhi P, Behera D et al. A comparison of non-tapering vs. tapering prednisolone in acute exacerbation of asthma involving use of the low-dose ACTH test. Int J Clin Pharmacol Ther. 2002; 40:256-62.
38. National Asthma Education and Prevention Program. Expert panel report: guidelines for the diagnosis and management of asthma update on selected topics-2002. J Allergy Clin Immunol. 2002; 110:S141-219.
39. Rowe BH, Edmonds ML, Spooner CH et al. Corticosteroid therapy for acute asthma. Respir Med. 2004; 98:275-84.
40. O'Driscoll BR, Kalra S, Wilson M et al. Double-blind trial of steroid tapering in acute asthma. Lancet. 1993; 341:324-7.